PAHC
Phibro Animal Health Corporation
PAHC has the edge over UNH overall, supported by stronger valuation and stronger fundamentals.
UNH
UnitedHealth Group Incorporated
UNH has lower modeled downside risk, despite its lower overall score.
PAHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Under pressure | |
| Stable |
PAHC's profitability is currently strong, and its revenue and balance sheet are stable, but its cash flow is under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
PAHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.8x | $35.46 | — |
| Cheap | 14x | $35.90 | +1.2% |
| Current | 14x | $35.46 | — |
| Fair | 21x | $52.34 | +48% |
| Expensive | 37x | $93.48 | +164% |
Historical ranges are pointers, not guarantees.
PAHC has the edge over UNH in the historical PE scenario, which offers more potential upside but is not a forecast.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
PAHC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
PAHC has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
PAHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.61 | +44% |
| Q3 2026 | $2.50 | +50% |
| Q2 2026 | $2.43 | +104% |
| Q1 2026 | $2.34 | +200% |
| Q4 2025 | $2.26 | +371% |
| Q3 2025 | $1.67 | +288% |
| Q2 2025 | $1.19 | +1883% |
| Q1 2025 | $0.78 | +144% |
| Q4 2024 | $0.48 | +33% |
PAHC has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
PAHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $386.8M | +6.3% |
| Q2 2026 | $396.7M | +4.8% |
| Q1 2026 | $383.5M | +10% |
| Q4 2025 | $373.9M | +21% |
| Q3 2025 | $363.9M | +40% |
| Q2 2025 | $378.7M | +39% |
| Q1 2025 | $347.8M | +32% |
| Q4 2024 | $309.3M | +24% |
PAHC has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -1.3 points |
| Q2 2026 | 12% | +3.2 points |
| Q1 2026 | 12% | +2 points |
| Q4 2025 | 13% | +5.2 points |
| Q3 2025 | 14% | +7.3 points |
| Q2 2025 | 8.9% | +2.2 points |
| Q1 2025 | 9.6% | +2.1 points |
| Q4 2024 | 8.3% | +2 points |
PAHC has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
PAHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $7.3M | +$11.8M |
| Q2 2026 | $5.2M | -36% |
| Q1 2026 | $890K | -97% |
| Q4 2025 | $8.3M | +$13M |
| Q3 2025 | -$4.5M | -248% |
| Q2 2025 | $8.1M | -47% |
| Q1 2025 | $35.4M | +2011% |
| Q4 2024 | -$4.7M | -123% |
PAHC still generates free cash flow, though less than at its 2025 peak: $22M over the past year.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over PAHC on cash flow, with more consistent year-over-year improvement.
PAHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -7K shares |
| 1 year | +0.2% | +80K shares |
| 3 years | +1.1% | +453K shares |
| 5 years | +1.1% | +453K shares |
| Available history | +1.1% | +453K shares |
PAHC has 41M diluted shares, about the same as a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over PAHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
PAHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.2x | Moderate |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 2.5x | Moderate |
| Q4 2025 | 2.6x | Moderate |
| Q3 2025 | 2.9x | Moderate |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | 4.2x | High |
| Q4 2024 | 4.8x | High |
PAHC's net debt is about 2.2 years of its operating earnings (EBITDA), down from 2.9 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH has the edge over PAHC on leverage, with a lower net debt burden relative to earnings.
PAHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.1 | Neutral |
| Stochastic | 36.1 | Neutral |
PAHC's weekly RSI is 46 (neutral) and its Stochastic is 36 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
PAHC PE vs Healthcare Sector
| Metric | PAHC | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 26x | 45% below |
| PE % | 15 | 29 | 14 pts below |
PAHC has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
PAHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.9 | 3.8% below |
| 20 week MA | $35.8 | 0.8% below |
| 50 week MA | $40.6 | 13% below |
| 100 week MA | $34.4 | 3% above |
| 200 week MA | $25.0 | 42% above |
PAHC has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 42% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over PAHC on trend strength, trading above more of its moving averages.
PAHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $24.8 | $19.1 | -23% |
| 2021 | $19.1 | $20.7 | +8.3% |
| 2022 | $20.7 | $13.9 | -33% |
| 2023 | $13.9 | $11.6 | -17% |
| 2024 | $11.6 | $21.1 | +82% |
| 2025 | $21.1 | $38.2 | +81% |
| 2026 YTD | $38.2 | $35.5 | -7.1% |
PAHC has finished lower in three of the last six years. It's down 7.1% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over PAHC on returns for 2026, with the stronger performance.